Motion filed includes evidence and testimony presented at trial demonstrating the lengths Johnson & Johnson MedTech’s Biosense Webster went to “crush” reprocessor competitors June 20, 2025 FOR IMMEDIATE RELEASE [Note to Editors: The case information discussed in this statement is publicly accessible on PACER and is summarized from the following documents, which AMDR has highlighted

[Washington, D.C. and Berlin, Germany / 5 June 2025] Today, Judge James V. Selna of the U.S. District Court for the Central District of California entered judgment in Innovative Health LLC v. Biosense Webster, Inc., tripling the jury’s May 16 award from $147 million to $442 million under federal and California antitrust statutes. The judgment

[Washington, D.C. and Berlin, Germany / 18 May 2025] Friday’s unanimous verdict by a federal jury in Santa Ana, California for Innovative Health against Johnson & Johnson (NYSE: JNJ) is a victory for America’s hospitals, providers, patients, and the environment. The jury found that Biosense Webster violated federal and state antitrust laws by withholding clinical

[Washington, DC / Berlin Germany – 22 April 2025] In commemoration of Earth Day, the Association of Medical Device Reprocessors and its members released the results of its 2024 member survey. Among the key findings (all data for 2024): Members helped health systems save $451,183,153 through cost savings (reprocessed “single-use” medical devices (SUDs) cost 30

The “Opt-In” Provision of the EU MDR (Article 17): Undermines EU Law and the Single Market Deprives Hospitals of Sustainable Medical Device Options, and Exacerbates Shortages in the Healthcare Supply Chain The time has come to change it. Summary Health systems are under enormous pressure. Urgently needed amendments to Article 17 of the EU Medical

[Washington, DC / Berlin Germany – 16 October 2024] A record 11,967 hospitals and surgical centers saved nearly half a billion dollars and eliminated greenhouse gas emissions equivalent to 7.5 Olympic swimming pools filled with gasoline by opting for regulated, commercially reprocessed 'single-use' medical devices (SUDs) instead of virgin SUDs in 2023. The data comes